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Objectives: to summarize existing evidence regarding the benefits and the risks of all available interventional and medical
means aimed at cardiac risk reduction in patients undergoing vascular surgery.
Design: review of the literature.
Materials and Methods: a critical review of all studies examining the impact of various prophylactic cardiac maneuvers
on perioperative outcome following vascular surgery was performed. Overall mortality, cardiac mortality and myocardial
infarction rate were used as the outcome measures.
Results: coronary artery bypass grafting is associated with a 60% decrease in perioperative mortality in patients under-
going vascular surgery, but in most of the cases this decrease does not outweigh the combined risk of the cardiac and the
subsequent noncardiac vascular procedure. Data supporting the cardioprotective effect of percutaneous transluminal
angioplasty in the perioperative setting are insufficient. b-blockade has been shown to decrease perioperative mortality
and cardiac morbidity in both high-risk (strong evidence) and low-risk (weak evidence) patients.
Conclusions: coronary revascularization is rarely indicated to simply get the patient through vascular surgery and should
be reserved for patients who would need it irrespective of the scheduled vascular procedure. Among all available pharma-
cological agents, including b-blockers, a-agonists, calcium channel blockers and nitrates, only b-blockers have been proven
to reduce the cardiac risk of vascular surgery.
Key Words: Vascular surgical procedures; Perioperative care; Postoperative complications; Myocardial revascularization;
Drug therapy.
Cardiac complications are the leading cause of mor-
bidity and mortality in patients undergoing periph-
eral vascular surgery.1,2 A review of the literature
reveals that coronary artery disease (CAD) is found
in 16±92% of patients with vascular disease, resulting
in a perioperative myocardial infarction (MI) rate of
0±8% and accounting for 40±60% of perioperative
deaths.2 To minimize cardiac risk of vascular surgery
we must first identify the patient at risk for cardiac
complications and then apply some prophylactic
measure aimed at reducing that risk. Such a measure
can be either interventional, in the form of coronary
artery bypass grafting (CABG) or percutaneous trans-
luminal coronary angioplasty (PTCA), or medical, in
the form of b-blockers, a-agonists, calcium channel
blockers, nitrates or anticoagulants. These two
strategies have not received equal attention. Extensive
research into cardiac risk stratification has documented
the sensitivity and specificity of various tests, includ-
ing clinical examination, exercise ECG, Holter
monitoring, dipyridamole thallium-201 imaging,
radionuclide ventriculography, dobutamine stress
echocardiography and coronary angiography.1,2 How-
ever, the efficacy of the various prophylactic measures
that might improve the outcome of patients under-
going vascular surgery has not yet been determined.
The purpose of this review is to summarize existing
evidence regarding the benefits and the risks of all
available interventional and medical means aimed at
cardiac risk reduction in patients undergoing vascular
surgery. A Medline search of the English-
language literature since 1975 was performed, using the
key words: vascular surgery, complications, myocar-
dial infarction, mortality, coronary revascularization,
drug therapy, b-blockers, a-agonists, calcium channel
blockers, nitrates and anticoagulants. Reference lists
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from all relevant articles were reviewed to identify
additional studies. Our search was limited to articles
using mortality or myocardial ischaemia as the out-
come measures.
Coronary Artery Bypass Grafting
Several studies in the late 70s3±5 demonstrated that
patients who underwent successful myocardial revas-
cularization carried a low risk of cardiac morbidity
and mortality following a subsequent vascular surgi-
cal procedure (Table 1). Despite the fact that all of the
patients included in these series had severe CAD trea-
ted by CABG, both perioperative mortality and MI
rate during the subsequent noncardiac procedure
were as low as 0±2.7%. It should be emphasized,
however, that all of these initial reports were retro-
spective and none of them had a control group.
Nine case controlled studies have been performed
since 1979, reporting on the perioperative outcome of
vascular patients with prior CABG.6±14 Summation
analysis of these studies reveals that vascular surgery
in patients who have undergone previous CABG is
associated with a mortality rate of 1.9% (18/958
patients), while mortality of patients without prior
CABG is 4.5% (379/8347 patients). These data corres-
pond to a 60% decrease in perioperative mortality,
achieved by CABG (relative risk (RR): 0.4, 95% confi-
dence interval (CI): 0.25±0.65, p5 0.001, w2 test). Simi-
larly, the incidence of perioperative MI is significantly
lower in patients with prior CABG (4/500 0.8%)
compared to those without prior CABG (61/
2491 2.4%), (RR: 0.32, 95% CI: 0.12±0.89, p 0.02,
Fisher's exact test). Cardiac mortality also proved to
be significantly lower in the prior CABG group (0/351
vs 39/2548 1.5%, p 0.01, Fisher's exact test).
Further analysis, according to the presence or not of
CAD in the control group, reveals that CABG patients
undergoing peripheral vascular surgery carry the
same risk of perioperative death (3/319 0.94% vs
16/1663 0.96%), cardiac death (0/144 vs 4/1630
0.25%) and MI (3/319 0.94% vs 14/1663 0.84%)
as patients without CAD. This risk is about 90%
lower than the perioperative risk of patients with
CAD who do not have previous coronary revascular-
ization: perioperative mortality in CABG patients is
0.94% (3/319) versus 6.4% (30/466) in patients with
medically treated CAD (RR: 0.14, 95% CI: 0.04±0.46,
p5 0.001, Fisher's exact test), cardiac mortality 0%
(0/144) versus 5.8% (21/360) (p 0.001, Fisher's
exact test) and MI rate 0.94% (3/319) versus 9.2%
(43/466) (RR: 0.09, 95% CI: 0.03±0.3, p5 0.001, Fisher's
exact test).
Based on the aforementioned studies and their
summation analysis, it seems that there is unanimity
regarding the protective effect that successful CABG
exertsduringasubsequentvascularsurgicalprocedure.
However, the key word is `` successful''. If CABG is to
be performed solely for prophylactic purposes, then
the risk of CABG should be added to the risk of the
subsequent vascular operation. Otherwise, one could
suggest that the coronary operation was simply a
survival test, potentially eliminating patients who
would have had cardiac complications following the
noncardiac procedure.15 Hertzer's7 report from the
Cleveland Clinic provides a characteristic example of
this additive risk. Perioperative mortality in this
analysis was 3.4% for the whole group of patients
undergoing aneurysm resection versus 1.6% for
those who had preliminary myocardial revasculariza-
tion. The respective values for lower extremity proce-
dures were 1.8% versus 0% and for extracranial
reconstructions 0.3% versus 0%. However, the peri-
operative mortality of the prophylactic CABG was
5.2%. Whether the benefits of prophylactic CABG
outweigh this risk is debatable, since we do not know
how these patients would have fared vascular surgery
without preliminary myocardial revascularization.
Cutler and Leppo16 have also questioned the benefit
of prophylactic CABG. In their series, five patients
underwent sequential coronary revascularization and
abdominal aortic aneurysm resection with no cardiac
complications. However, a sixth patient died of haem-
orrhagic pancreatitis after CABG and a seventh died
of a ruptured aortic aneurysm after catheterization but
before coronary surgery. An eighth patient with severe
aortoiliac disease suffered a cerebrovascular accident
after transaxillary coronary angiography. These
results clearly illustrate the wide range of complica-
tions associated with preliminary CABG. Apart from
the obvious surgical risk of the CABG itself, these
complications also include untoward events during
angiography as well as the risk of delaying vascular
reconstruction. All of these factors should be taken
into account and treatment plans designed to reduce
the incidence of cardiac events in patients with
peripheral vascular disease should be thoughtfully
individualized.
Two decision analysis methodologies have been
published and several important conclusions can be
drawn from these models. First, the approach should
be locally validated, based on the institutional mortal-
ity associated with coronary revascularization and the
institutional mortality associated with the surgical pro-
cedure performed without preoperative intervention.17
In the case of AAA repair, prophylactic CABG is
unequivocally justified only when the mortality from
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AAA surgery in patients with severe CAD is higher
than 9.5%. The decision analysis by Mason et al.18
reached similar conclusions, indicating that vascular
surgery without preoperative coronary angiography
and selective CABG generally leads to better out-
comes. Preoperative CABG reduces overall mortality
only when the estimated operative mortality of the
noncardiac vascular surgery is substantially higher
than 5% and the estimated operative mortality of
coronary revascularization is relatively low (in the
2±3% range).
All of the above mentioned comparisons, however,
can be criticized as being unfair against prophylactic
CABG. The point of criticism is that they compare
perioperative risks of the two strategies ignoring the
fact that the risks of CABG are limited to the periopera-
tive period, while its benefits may be evident for sev-
eral years. Indeed, Hertzer's reports from the
Cleveland Clinic19,20 showed that the 5-year mortality,
including perioperative deaths, of patients with periph-
eral vascular disease who had had coronary revascu-
larization was half as the mortality of patients with
severe CAD for whom CABG was warranted but
never performed (28% vs 57%, p 0.001).19 The protec-
tion from cardiac-related death offered by myocardial
revascularization was most apparent among men,
hypertensives and nondiabetics.20 Using prospectively
collected data from the CASS registry, Rihal et al.21
verified the long-term benefits of CABG in patients
with vascular disease. In a cohort of 1834 patients
with both coronary artery and peripheral vascular dis-
ease, the estimated probabilities of survival at 4, 8, 12
and 16 years were 88, 72, 55 and 41%, respectively, for
the CABG group versus 73, 57, 44 and 34%, respective-
ly, for the medical group (p5 0.0001). Multivariate
analysis showed that the type of therapy given was
an independent predictor of survival, while subgroup
analysis demonstrated that the benefits of surgical
treatment on survival were limited to patients with
three-vessel CAD and were inversely related to the
ejection fraction. The results of the European
Coronary Surgery Study,22 which is the only rando-
mized, controlled study on the subject available to
date, confirm these findings. The presence of periph-
eral vascular disease was associated with greatly
decreased 8-year survival in both medically treated
(81 vs 57.1%) and surgically treated (90 vs 84.8%)
patients with CAD. However, the surgical strategy low-
ered the mortality rates by 65% in patients with periph-
eral vascular disease (from 42.9 to 15.2%), whereas in
patients without peripheral vascular disease the
respective value was 47% (from 19 to 9%). In other
words, CABG proved to be more beneficial in patients
with peripheral vascular disease than in those without.
Based on all the available data, the ACC/AHA Task
Force Committee has published guidelines for the
preoperative use of coronary revascularization.23
According to these guidelines, indications for CABG
before noncardiac surgery are identical to those for
CABG in general. CABG is rarely indicated to simply
`` get the patient through'' noncardiac surgery and
should be reserved for patients scheduled for elective
noncardiac surgical procedures of high or intermedi-
ate risk who are found to have prognostic high-risk
coronary anatomy and in whom long-term outcome
would likely be improved by CABG. The much
awaited results of the first randomized trial on the
use of prophylactic coronary artery revascularization
for elective vascular surgery will help refine these
recommendations and support them with currently
lacking level one evidence.24 This Veterans Adminis-
tration study will also address important secondary
issues such as the cost-effectiveness of various treat-
ment strategies and the quality of life offered by each of
them (coronary revascularization vs medical therapy).
Another question that needs to be answered relates
to the optimal timing of prophylactic coronary revas-
cularization. Several studies have shown that CABG
and AAA repair, or CABG and carotid endarterect-
omy can be safely performed simultaneously in
appropriately selected patients.25,26 On the contrary,
some other authors stand by the staged approach,
showing that simultaneous operations carry an
increased perioperative risk.27,28 With a lack of a def-
inite answer regarding the appropriate timing of
CABG and peripheral vascular surgery, the current
recommendation is that the therapeutic approach
should be individualized, based on the patient's
coronary status and the urgency of the upcoming
vascular operation.29
Percutaneous Transluminal Coronary
Angioplasty
There are few studies examining the impact of PTCA
on the risk of subsequent noncardiac surgery (Table 2).
Of these, only four have focused on vascular surgery
and, as with CABG, none of them is randomized.
Two early reports have shown that the rate of major
complications after noncardiac surgery is low in
patients submitted to prior PTCA.30,31 Specifically,
mortality rate was between 1.9 and 2.7%, while the
incidence of MI was 0.7±5.6%. However, without a
comparison group, it is debatable whether a MI rate
of 5.6% can be considered low.
The first case controlled study on the subject
was performed by Elmore et al.32 in 1993. This study
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compared perioperative as well as long-term results of
AAA repair between patients submitted to prophylac-
tic PTCA or CABG. Both strategies achieved similar
good results with regards to perioperative MI (0 vs 5.8%
respectively), perioperative mortality (0% in both
groups) and 3-year survival (92.3 vs 82.8% respec-
tively). However, patients chosen for PTCA had sig-
nificantly more late cardiac events including recurrent
angina, MI and congestive heart failure, than those
who underwent CABG (56.5 vs 27.3% respectively at
3 years). This finding is of particular importance if we
take into account that patients selected for PTCA had
significantly less 3-vessel disease on angiography than
those scheduled for CABG. The less favorable long-
term outcome in the PTCA group was attributed to
the substantial rate of restenosis which is known to
accompany PTCA.
An interesting analysis, stratified according to the
type of vascular surgery, was performed by Fleisher
et al.13 In this study, coronary revascularization,
either in the form of PTCA or CABG, resulted in
significantly lower perioperative mortality in patients
undergoing aortic surgery when compared to the out-
come of patients not submitted to any preoperative
testing or those submitted to stress testing alone (with-
out coronary revascularization). On the contrary,
PTCA or CABG were not associated with reduced
perioperative mortality after infrainguinal surgery.
Of course, as in any other retrospective study, inter-
pretation of these results is limited since the compari-
son groups probably had different comorbidities. In
this context, the above-mentioned results might also
suggest that PTCA or CABG reduce perioperative
mortality of infrainguinal revascularization to levels
comparable to those of patients in whom preoperative
coronary revascularization is not warranted. This
theory, however, is not supported by the findings of
Back et al.14 In their series, perioperative mortality
of patients with previous coronary revascularization
was not significantly different from that of patients
without revascularization (3.1 vs 1.1%, p 0.2) and,
in fact, it was almost the same as the mortality of the
high-risk subgroup of patients without previous
CABG or PTCA (3.1 vs 3.3%, p 1.0). On the other
hand, there was a trend towards lower perioperative
mortality in patients with CABG within 5 years or
PTCA within 2 years than in patients with remote
revascularization (1.3 vs 6.3%).
In view of the contradictory results of retrospective
series and in the absence of any prospective, rando-
mized study, the ACC/AHA Task Force Committee
has suggested that, until further data are available,
indications for percutaneous coronary interventions
in the perioperative setting should be similar to the
indications under nonoperative situations.23 As for the
optimal timing of the two procedures, it is recom-
mended that surgery should be delayed for at least
one week after balloon angioplasty to allow healing of
the disrupted endothelium. This delay will also allow
the prothrombotic effects of the noncardiac surgery
not to be added to those of the cardiac intervention.
On the other hand, the time interval between the cor-
onary and the peripheral vascular procedure should
not exceed one month, since restenosis after PTCA
usually occurs within 2±5 months.
In order to improve immediate angioplasty results
and reduce the rate of subsequent restenosis, coronary
stents are being used with increased frequency
nowadays. Despite their wide use, there is only one
study examining the perioperative course of patients
who have previously undergone coronary stent place-
ment.34 This study revealed a mortality of 20%, MI
Table 2. Perioperative outcome of patients with prior PTCA.
Author No. of procedures Purpose of
PTCA 
Type of
procedures
Mortality (%) Cardiac mortality (%) MI (%)
Prior PTCA Control Prior PTCA Control Prior PTCA Control Prior PTCA Control
Allen,30 1991 193 C 33% vascular 2.1 0.5 0.5
Huber,31 1992 54 A 52% vascular 1.9 1.9 5.6
Elmore,32 1993 14 86 y A AAA 0 0 0 0 0 5.8
Gottlieb,33 1998 194 C Vascular 0.5 0.5 0.5
Fleisher,13 1999 60 665±1410 z A AAA 3.3 4.1±9
54 338±1958z A Infrainguinal 9.3 3.6±6.6
Back,14 2002 28 353 x C Vascular 7.1 1.1
KaøuzÇa,34 2000 40{ A 73% vascular 20 15 17.5
All of the studies included in the table are retrospective. Purpose of PTCA in relation to the non-cardiac surgery: APTCA performed in anticipation of the subsequent operation, Cpatients
had previous PTCA coincidentally.
y Patients with prior CABG.
z Patients submitted to stress testing alone (without coronary revascularization) ± no preoperative testing.
x Patients operated on during the same time period without prior PTCA.{ Patients submitted to coronary stenting.
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rate of 17.5% and an incidence of bleeding episodes of
27.5% among 40 patients who underwent noncardiac
surgery less than 6 weeks after coronary stent place-
ment. Interestingly, all deaths and MIs as well as 73%
of the bleeding episodes occurred in patients sub-
jected to surgery less than 14 days from stenting.
Further investigation by electrocardiography, angiog-
raphy and enzymatic tests showed that most of the
fatal events were due to stent thrombosis, which, in
turn, was attributed to interruption of one or both
antiplatelet drugs before surgery. On the other hand,
bleeding complications occurred more frequently in
patients who had no discontinuation of either medica-
tion before surgery. Thus, as KaøuzÇa et al.34 remark,
stent implantation before surgery appears to be a
double-edge sword. Withholding the antiplatelet
drugs increases the risk of stent thrombosis, while
their continuation increases the risk of bleeding. In
order to overcome these problems, noncardiac surgery
should be postponed for at least 2 weeks and ideally
4±6 weeks after coronary stenting to allow complete
endothelization of the stent before antiplatelet
therapy is interrupted. If the noncardiac operation
cannot be delayed, stent placement should be avoided
if possible.
Medical Treatment
Several pharmacological agents including b-blockers,
a-agonists, calcium channel blockers and nitrates have
been utilized to reduce the cardiac risk of vascular
surgery (Table 3). Among these, only b-blockers have
been shown to effectively achieve this goal.
b-blockers
Two case controlled studies by Pasternack et al.35,49
published in the late 80's, showed that perioperative
metoprolol in patients undergoing peripheral vascular
surgery resulted in significantly lower perioperative
MI rate (3.1 vs 17.6% in the control group)35 and less
intraoperative ischaemia with respect to duration and
frequency of episodes.49 Yeager et al.50 confirmed the
cardioprotective effects of b-blockers using a reverse
study design. Instead of comparing perioperative out-
come between patients receiving b-blockers and those
receiving standard medical care only, they compared
the use of perioperative b-blockers in a group
of patients with perioperative MI and a matched
group of randomly selected controls. The study
Table 3. Perioperative outcome of patients receiving cardioprotective medical therapy.
Author No. of procedures Type of procedures Mortality (%) Cardiac mortality (%) MI (%) Ischaemia (%)
Drug Control Drug Control Drug Control Drug Control Drug Control
b-blockers
Pasternack,35 1987 32 51 AAA 3.1 2 3.1 17.6
Wallace,36 1998 99 101 40% vascular 4 2 1 2 1 2 24.2 38.6
Poldermans,37 1999 59 53 Vascular 3.4 17 3.4 17 0  17
Raby,38 1999 15 11 Vascular 0 9.1 33 73
a-agonists
Ellis,39 1994 30 31 3.6 y±21.4 z 20.8 y±19.2 z
Talke,40 1995 18 6 Vascular 0 0 0 1
Stuhmeier,41 1996 145 152 Vascular 1.4 0.7 0  2.6  24 y 39 y
Mangano,42 1997 98±99 x 103 Vascular 1±0 1 2±1 5.8 19.5±22.6 34.3
Oliver,43 1999 454 450 Vascular 1.8 4.4 1.3 4 9.3 11.8
CCBs
Godet,44 1987 15 15 Vascular 0 0 0 0 0 0 40 73
Nitrates
Coriat,45 1984 23 a 22 b 84% vascular 0 0 17.4 63.6
Dodds,46 1993 22 23 82% vascular 0 0 0 4.3 31.8 30.4
Heparin
Thompson,47 1996 145 139 AAA 4.1 7.9 1.4 5.8 2.1 8.6
Samson,48 2002 103 146 AAA 3.9 1.4 2.9 0 2.9 0
All of the studies included in the table are randomized, except for the study by Pasternack et al.35 in which matched controls were used and
the study by Samson et al.48 in which heparin was used selectively based on criteria described by the authors. Nonfatal MIs only.
y Intraoperatively.
z Postoperatively.
x Patients receiving iv mivazerol at a dose of 1.5 mg/kg/h ± patients receiving iv mivazerol at a dose of 0.75mg/kg/h.
a Patients receiving iv nitroglycerin at a dose of 1.0mg/kg/min.
b Patients receiving iv nitroglycerin at a dose of 0.5 mg/kg/min.
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demonstrated that b-blockers had been used less fre-
quently in patients with perioperative MI than in con-
trol patients without perioperative MI (30 vs 50%,
p 0.01). Overall, b-blockade was associated with a
50% reduction in perioperative MI (p 0.03).
The most convincing data available to date regard-
ing the benefits of perioperative b-blockade come
from two recent randomized trials. The first was a
double-blind, placebo-controlled trial by Mangano
et al.51 The b1 selective antagonist atenolol was admin-
istered intravenously before and immediately after
surgery (40% major vascular procedures) and orally
thereafter until the patient was discharged from the
hospital (up to a maximum of 7 days). Overall mor-
tality after discharge was significantly lower among
the atenolol-treated patients than among the placebo
group at 6 months (0 vs 8%, p5 0.001), 1 year (3 vs
14%, p5 0.005) and 2 years (10 vs 21%, p 0.01). Peri-
operative b-blockade appeared to be safe, well
tolerated and cost-effective with an overall cost per
life-year saved of $2500 based on the most conserva-
tive assumption.
The rationale of the prolonged cardiac protection
offered by perioperative b-blockade is that long-term
adverse outcomes after noncardiac surgery are signifi-
cantly more frequent in patients who have suffered
one or more episodes of perioperative myocardial
ischaemia. Indeed, a subsequent report by the same
group36 showed that an episode of myocardial ischae-
mia during postoperative days 0±2 increased the RR of
death during the next 2 years by a factor of 2 (26 vs
13%; RR: 2.06, 95% CI: 1.04±4.06). This study also
showed that atenolol reduced the incidence of myo-
cardial ischaemia during the postoperative days 0±2
(17.2 vs 33.7%, p 0.008) and 0±7 (24.2 vs 38.6%,
p 0.029). However, there were no differences
between the two treatment groups in the incidence
of in-hospital cardiac death, noncardiac death and
MI. The failure to detect any such differences was
due to the low incidence of these adverse outcomes
(53%). More than 1500 patients per group would be
required to have an 80% chance of detecting a 50%
reduction in an event with an incidence of 3%, while,
in this study, only 99 patients were randomized in the
atenolol group and 101 in the placebo group.
The second randomized trial on the perioperative
and long-term results of b-blockade during vascular
surgery was performed by Poldermans et al. and was
published in two parts in 199937 and 2001.52 In this
study, bisoprolol reduced the perioperative incidence
of both death from cardiac causes (3.4% in the
bisoprolol group vs 17% in the standard-care group,
p 0.02) and nonfatal MI (0 vs 17% respectively,
p5 0.001).37 Thus, the number of patients needed to
be treated with bisoprolol in order to prevent one
death or nonfatal MI was only 3. This result prompted
the safety committee to interrupt the study after the
planned interim analysis.
A subsequent report by the same group52 showed
that, during the 2-year follow-up, the composite end-
point of either cardiac death or nonfatal MI occurred
in 12% of the patients receiving bisoprolol versus 32%
of those receiving standard care only (odds ratio: 0.3,
95% CI: 0.11±0.83). The cardioprotective effect of
bisoprolol was similar between patients with limited,
moderate or extensive stress-induced ischaemia.
Based on these data, the ACC/AHA Task Force
Committee23 has recommended the perioperative
administration of b-blockers in all patients under-
going vascular surgery who have signs of ischaemia
on preoperative testing. b-Blockers should also be
administered in patients who have used them in the
recent past for the treatment of angina as well as in
patients with symptomatic arrhythmias or hyperten-
sion. The mere presence of major risk factors for CAD
is also considered a relative indication for the peri-
operative administration of b-Blockers. This indication
gains particular importance in vascular surgery since
the majority of vascular patients will fall within this
category. As for the treatment plan, administration of
b-blockers should ideally start at least one week before
elective surgery with the dose individualized to
achieve a resting heart rate of 50±60 beats/min.
The efficacy of b-blockade in low risk patients is less
well established since the randomized trials cited
above were performed in selected, high risk patients.
Recently, a cohort multicenter study by Boersma et al.53
including 1351 patients scheduled for elective major
vascular surgery showed that the utility of b-blockade
extended in the low risk subgroup of patients as well.
Among this subgroup, the composite end-point of
perioperative death or MI occurred in 0.8% (2/263)
of patients receiving b-blockers, compared to 2.3%
(20/855) of patients who did not receive b-blockers.
The respective values in the high risk subgroup were
6.2% (6/97) versus 12.5% (17/136). Although the
retrospective nature of this study limits the interpret-
ation of its data, it seems that all patients undergoing
vascular surgery may benefit from perioperative
b-blockade irrespective to risk category.
A drawback of b-blockers is their potential side-
effects including hypotension, bradycardia, congest-
ive heart failure and bronchospasm. In this context, a
cardioselective b-blocker with short half-life, such as
esmolol, might be advantageous. Only two studies
have assessed the role of esmolol in the perioperative
setting. The first study, by Cucchiara et al.54 showed
that esmolol was effective in blunting the increases in
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heart rate and arterial blood pressure during and fol-
lowing endotracheal intubation in patients under-
going carotid endarterectomy without an increase in
adverse effects. The second study, by Raby et al.38
demonstrated that patients receiving esmolol during
vascular surgery had fewer episodes and a shorter
duration of perioperative ischaemia as compared
with patients receiving placebo. Multivariate analysis
showed that it was only heart rate control that inde-
pendently predicted postoperative ischaemia and not
esmolol administration.
a-agonists
Five randomized, double-blind, placebo controlled
trials have examined the role of a2-agonists in patients
having noncardiac surgery. In the first of these studies,
Ellis et al.39 tested the hypothesis that the addition of
clonidine to a standardized general anesthetic could
decrease the incidence of perioperative myocardial
ischaemia in patients with known CAD or at least
two atherosclerotic risk factors. The study showed
that clonidine safely reduced the incidence of intrao-
perative myocardial ischaemia from 21.8 to 3.6%,
while it failed to decrease the incidence of postopera-
tive myocardial ischaemia (placebo: 19.2%, clonidine:
21.4%), possibly due to inadequate dosing. All of the
patients in this series underwent major noncardiac
surgery, the exact type of which is not reported.
A second study, by Talke et al.40 showed that the a2-
agonist dexmedetomidine improved perioperative
haemodynamic management of patients undergoing
vascular surgery. However, the study was too small to
detect differences in clinical outcome.
A much larger study was performed by Stuhmeier
et al.41 in 1996 and showed that the administration of
clonidine 90 min before scheduled induction of anes-
thesia reduced the incidence of perioperative myocar-
dial ischaemic episodes from 39 to 24% in patients
undergoing vascular surgery (29% supraaortic, 36%
aortic and 35% infraaortic reconstructions). Neverthe-
less, the rate of fatal cardiac events and nonfatal MIs
was not different between the clonidine and the
placebo group.
Similar results were reported in another study by
the McSPI (Multicenter Study of Perioperative Ische-
mia) group42 which included 317 patients from 23
medical centers in 7 European countries. Perioperative
administration of the a2-adrenergic receptor agonist
mivazerol proved to be safe and efficacious in
improving haemodynamic stability in patients under-
going vascular surgery (excluding aortic procedures).
In addition, the higher of the two doses of mivazerol
that were evaluated (1.5 vs 0.75 mg/kg/h) achieved a
significant reduction in the incidence of intraoperative
myocardial ischaemia, from 34.3 to 19.5%. However,
the high dose, low dose and placebo groups did not
differ in the rate of MI (2, 1 and 5.8%, respectively) or
in the incidence of cardiac death (1, 0 and 1% respec-
tively). As the authors comment, the relatively small
sample size limits the ability to interpret these results
and they suggest the need for larger-scale trials that
would define the effect of mivazerol on cardiovascular
outcome.
Such a study was published two years later and
included 2854 patients from 61 European centers.43
In this trial (the European Mivazerol Trial ± EMIT),
mivazerol failed to reduce the rate of MI, overall
mortality or the composite endpoint of MI or death
in patients with established CAD undergoing noncar-
diac surgery. However, a subgroup analysis, focused
on 904 patients undergoing vascular surgery, showed
that there were fewer composite endpoints (MI or
death) in those receiving mivazerol (RR: 0.67), fewer
cardiac deaths (RR: 0.33) and less overall mortality
(RR: 0.41), although the incidence of perioperative
MI was not significantly altered. It seems that a2-
agonists, such as mivazerol, may be protective for
patients with CAD undergoing vascular surgery,
though further trials, specifically designed to test this
hypothesis, are needed before final recommendations
can be issued.
Calcium channel blockers
To date, there has been only one prospective study
examining the role of calcium channel blockers in
patients undergoing vascular surgery.44 This was a
randomized, double-blind, placebo controlled trial
but very small, with only 15 patients allocated to
each group. Despite the small size of the study groups,
intravenous administration of diltiazem was found to
be effective in reducing the incidence of intraoperative
myocardial ischaemia (from 73 to 40%) during carotid
endarterectomy or aortobifemoral bypass grafting. On
the other hand, there were no perioperative MIs in
either group, most probably due to their small size.
Larger trials are needed before definite conclusions
can be drawn.
The retrospective review by Yeager et al.50 also
failed to show any benefit associated with the admin-
istration of calcium channel blockers in terms of peri-
operative MI reduction. In this study, 49% of the
patients with perioperative MI had received calcium
channel blockers during vascular surgery, while
the respective value in matched patients without
perioperative MI was 42% (pNS). In conclu-
sion, existing data do not currently support the
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perioperative use of calcium channel blockers as a
prophylactic treatment against cardiac events.
Nitrates
Two randomized trials have sought to determine the
role of iv nitroglycerin in the prevention of intraopera-
tive or perioperative myocardial ischaemia in patients
undergoing noncardiac surgery (mostly vascular). The
first study45 randomly assigned patients to two differ-
ent dosing schemes of intraoperative nitroglycerin (0.5
and 1.0 mg/kg/min). The higher dose resulted in a
significantly lower incidence of myocardial ischaemia
(63.6 vs 17.4%), whereas no intraoperative MIs
occurred in any of these groups. The small size of
the trial (45 patients) does not allow definite conclu-
sions to be drawn.
The second randomized trial46 was equally small
(45 patients) but differed from the first study in that
it compared the outcome of patients receiving 0.9 mg/
kg/min of iv nitroglycerin with the outcome of
patients not receiving prophylactic nitroglycerin at
all. Despite this study design, no difference in the
incidence of myocardial ischaemia was found
between the two groups (nitroglycerin group: 31.8%,
control group: 30.4%), or in the incidence of MI (0 vs
4.3%, respectively).
Based on these data, the prophylactic use of nitro-
glycerin cannot be recommended. Until larger trials,
sufficiently powered to detect differences in the hard
endpoints of MI or death, are available, intraoperative
administration of nitroglycerin should be limited to
patients with ongoing myocardial ischaemia without
hypotension.
Heparin
A multicenter randomized trial,47 published in 1996,
showed that the use of intraoperative heparin during
elective AAA repair reduced the incidence of peri-
operative MI from 8.6 to 2.1% (p 0.02). The authors
speculate that dilatation of the left ventricle after
aortic cross-clamping leads to coronary artery plaque
fissuring, with heparin preventing subsequent throm-
bosis. Their findings, however, were not reproduced
by a recent retrospective study by Samson et al.,48 in
which selective use of heparin during AAA repair was
not associated with a decrease in perioperative MI rate.
Approach to the Patient
The suggested decision model (Fig. 1) starts with an
evaluation of the urgency of the vascular operation. In
case of a real emergency which necessitates immediate
intervention, the patient should proceed directly to the
operating room, since there will be neither enough
time for a formal cardiac assessment nor any other
therapeutic alternative. In case of an urgent or an
elective operation, a routine cardiac evaluation should
be performed, including clinical examination and rest-
ing ECG. If the ECG is negative and the patient is at
low cardiac risk, in terms of concomitant atheroscler-
otic risk factors,23,55 he/she should be cleared to go to
the operating room. Perioperative b-blockade may be
helpful in such cases (weak evidence). High-risk
patients scheduled for vascular surgery as well as
patients with positive or equivocal results of routine
preoperative testing should be submitted to further
noninvasive tests, including exercise or pharmaco-
logical stress test and dipyridamole thallium ima-
ging.1 If the results of these tests are negative, the
patient should proceed to the operating room under
b-blocker prophylaxis (strong evidence). If noninva-
sive testing is positive, then a coronary angiogram is
warranted. Nondiabetic patients with 1 or more sig-
nificant lesions in 1 or 2 coronary arteries suitable for
angioplasty should undergo PTCA, provided the ves-
sels to be dilated subtend a large area of viable myo-
cardium.56 Patients with three-vessel disease, those
with two-vessel disease and significant proximal left
anterior descending coronary artery stenosis as well as
those with significant left main coronary artery sten-
osis or left main equivalent should undergo CABG.57
In cases of severe, inoperable lesions, modification
of the operative approach should be considered.
Endovascular instead of open repair of AAA and
extra-anatomic instead of aortobifemoral bypass for
aortic occlusive disease might be reasonable alterna-
tives. If modification of surgery is not feasible, then
the surgical risk and the risk posed by the peripheral
vascular disease should be balanced. If the estimated
risk of the operation is higher than the risk posed by
the peripheral vascular disease, then the operation
should be cancelled. If the risk of the peripheral vas-
cular disease is higher, the patient should proceed to
the operating room under b-blockade. In any case,
close cooperation between the vascular surgeon, the
cardiologist and the anaesthesiologist is a `` sine qua
non'', with the vascular surgeon assessing the risk
posed by the vascular disease and potentially modify-
ing the surgical approach, the cardiologist deciding on
the appropriate diagnostic work-up and setting the
indication for coronary revascularization and the
anaesthesiologist involved in both risk assessment
and perioperative risk reduction.
Undoubtedly, contemporary advances in noninva-
sive testing, perioperative management and surgical
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or interventional techniques have made the treatment
of patients with concomitant cardiac and peripheral
vascular disease reasonably safe in most of the cases.
However, several areas are in need of further research.
Apart from the classic disruption of the myocardial
oxygen supply-demand balance, the pathophysiology
of perioperative MI possibly involves the vascular
endothelium, the mechanism of coagulation, the sys-
temic inflammatory response as well as the effect of
haemodynamic forces, such as shear stress, on
unstable coronary plaques. Clarification of these
pathologic processes will allow better risk stratifica-
tion and further reduction of cardiac complications of
vascular surgery in the future.
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